Brief: Nyxoah: FDA Breakthrough Device Designation Granted For Genio System
Sept 14 (Reuters) - Nyxoah SA NYXH.BR :
* NYXOAH ANNOUNCES U.S. FDA BREAKTHROUGH DEVICE DESIGNATION
GRANTED FOR THE GENIO SYSTEM FOR OBSTRUCTIVE SLEEP APNEA AND
COMPLETE CONCENTRIC COLLAPSE
Source text for Eikon: ID:nGNE1kM3zf
Further company coverage: NYXH.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Nyxoah SA
See all newsBelgium's Nyxoah Q3 revenue rises on US commercialization
Brief: Nyxoah SA Q3 Gross Profit EUR 5.785 Million
Brief: Nyxoah SA Submits Pma Supplement To FDA To Expand Genio Indication To Complete Concentric Collapse Patients
Brief: Nyxoah Says Co Appoints Liam Kelly As Chief Executive Officer Effective October 1
Brief: Cvrx Appoints John Landry As Chief Financial Officer